GlassScriptPhysician profile
Swati M Purohit
NPI 1083715627
$1,196.74
in general payments reported to CMS, 2019-2025
18 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.07 · 2020: $113 · 2021: $408 · 2022: $140 · 2023: $197 · 2024: $110 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $504.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $275.36 | 2020-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Sunovion Pharmaceuticals INC. | $203.59 | 2020-2021 | |
| Glaxosmithkline, LLC. | $107.96 | 2021-2025 | Bexsero, Rotarix, Pediarix |
| Pfizer INC. | $98.06 | 2019-2024 | |
| Alkermes, INC. | $68.05 | 2021 | |
| Sanofi Pasteur INC. | $57.69 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $56.77 | 2020-2025 | Invega Trinza, Invega Sustenna |
| Insulet Corporation | $48.25 | 2025 | Omnipod |
| Cranial Technologies, INC | $48.20 | 2020-2023 | Doc Band |
| Otsuka America Pharmaceutical, INC. | $43.34 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.50 | 2021 | |
| Novo Nordisk INC | $36.61 | 2022-2025 | Wegovy |
| Neurocrine Biosciences, INC. | $29.16 | 2021 | |
| Hologic Sales and Service, LLC | $25.00 | 2023 | Aptima |
| Roche Diagnostics Corporation | $17.74 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $15.77 | 2022 | |
| Lundbeck LLC | $13.95 | 2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $13.74 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swati Purohit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.